Here's what that looks like: The Retatrutide Escalation Protocol (Phase 2 Trial Structure) Weeks 1-4: 2 mg subcutaneous injection, once weekly Weeks 5-8: 4 mg once weekly Weeks 9-12: 8 mg once weekly Weeks 13-16: 12 mg once weekly (highest dose arm) Week 17+: Maintenance at the highest tolerated dose In the Phase 2 trial published in The New England Journal of Medicine , participants in the highest dose group (12 mg) lost a mean of 24.2% of body weight at 48 weeks
PlexusDx's pricing model reflects this reality: your dose may need to go up, but your price won't, keeping treatment cost predictable as providers optimize therapy
Weight loss typically accelerates as you reach higher doses
Full Certificates of Analysis are published for every product and every lot
The body of evidence across multiple studies in various countries is conclusive that treatment with GLP-1 medications for type 2 diabetes and/or overweight/obesity is strongly associated with an elevated risk of developing NAION
Nitric oxide is involved in blood vessel tone, tissue perfusion, endothelial function, inflammation and oxidative balance
